Cargando…

Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study

BACKGROUND: Escherichia coli is the most common cause of bloodstream infections (BSIs) and mortality is an important aspect of burden of disease. Using a multinational population-based cohort of E. coli BSIs, our objectives were to evaluate 30-day case fatality risk and mortality rate, and determine...

Descripción completa

Detalles Bibliográficos
Autores principales: MacKinnon, Melissa C., McEwen, Scott A., Pearl, David L., Lyytikäinen, Outi, Jacobsson, Gunnar, Collignon, Peter, Gregson, Daniel B., Valiquette, Louis, Laupland, Kevin B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229717/
https://www.ncbi.nlm.nih.gov/pubmed/34172003
http://dx.doi.org/10.1186/s12879-021-06326-x
_version_ 1783713043508625408
author MacKinnon, Melissa C.
McEwen, Scott A.
Pearl, David L.
Lyytikäinen, Outi
Jacobsson, Gunnar
Collignon, Peter
Gregson, Daniel B.
Valiquette, Louis
Laupland, Kevin B.
author_facet MacKinnon, Melissa C.
McEwen, Scott A.
Pearl, David L.
Lyytikäinen, Outi
Jacobsson, Gunnar
Collignon, Peter
Gregson, Daniel B.
Valiquette, Louis
Laupland, Kevin B.
author_sort MacKinnon, Melissa C.
collection PubMed
description BACKGROUND: Escherichia coli is the most common cause of bloodstream infections (BSIs) and mortality is an important aspect of burden of disease. Using a multinational population-based cohort of E. coli BSIs, our objectives were to evaluate 30-day case fatality risk and mortality rate, and determine factors associated with each. METHODS: During 2014–2018, we identified 30-day deaths from all incident E. coli BSIs from surveillance nationally in Finland, and regionally in Sweden (Skaraborg) and Canada (Calgary, Sherbrooke, western interior). We used a multivariable logistic regression model to estimate factors associated with 30-day case fatality risk. The explanatory variables considered for inclusion were year (2014–2018), region (five areas), age (< 70-years-old, ≥70-years-old), sex (female, male), third-generation cephalosporin (3GC) resistance (susceptible, resistant), and location of onset (community-onset, hospital-onset). The European Union 28-country 2018 population was used to directly age and sex standardize mortality rates. We used a multivariable Poisson model to estimate factors associated with mortality rate, and year, region, age and sex were considered for inclusion. RESULTS: From 38.7 million person-years of surveillance, we identified 2961 30-day deaths in 30,923 incident E. coli BSIs. The overall 30-day case fatality risk was 9.6% (2961/30923). Calgary, Skaraborg, and western interior had significantly increased odds of 30-day mortality compared to Finland. Hospital-onset and 3GC-resistant E. coli BSIs had significantly increased odds of mortality compared to community-onset and 3GC-susceptible. The significant association between age and odds of mortality varied with sex, and contrasts were used to interpret this interaction relationship. The overall standardized 30-day mortality rate was 8.5 deaths/100,000 person-years. Sherbrooke had a significantly lower 30-day mortality rate compared to Finland. Patients that were either ≥70-years-old or male both experienced significantly higher mortality rates than those < 70-years-old or female. CONCLUSIONS: In our study populations, region, age, and sex were significantly associated with both 30-day case fatality risk and mortality rate. Additionally, 3GC resistance and location of onset were significantly associated with 30-day case fatality risk. Escherichia coli BSIs caused a considerable burden of disease from 30-day mortality. When analyzing population-based mortality data, it is important to explore mortality through two lenses, mortality rate and case fatality risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06326-x.
format Online
Article
Text
id pubmed-8229717
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82297172021-06-28 Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study MacKinnon, Melissa C. McEwen, Scott A. Pearl, David L. Lyytikäinen, Outi Jacobsson, Gunnar Collignon, Peter Gregson, Daniel B. Valiquette, Louis Laupland, Kevin B. BMC Infect Dis Research BACKGROUND: Escherichia coli is the most common cause of bloodstream infections (BSIs) and mortality is an important aspect of burden of disease. Using a multinational population-based cohort of E. coli BSIs, our objectives were to evaluate 30-day case fatality risk and mortality rate, and determine factors associated with each. METHODS: During 2014–2018, we identified 30-day deaths from all incident E. coli BSIs from surveillance nationally in Finland, and regionally in Sweden (Skaraborg) and Canada (Calgary, Sherbrooke, western interior). We used a multivariable logistic regression model to estimate factors associated with 30-day case fatality risk. The explanatory variables considered for inclusion were year (2014–2018), region (five areas), age (< 70-years-old, ≥70-years-old), sex (female, male), third-generation cephalosporin (3GC) resistance (susceptible, resistant), and location of onset (community-onset, hospital-onset). The European Union 28-country 2018 population was used to directly age and sex standardize mortality rates. We used a multivariable Poisson model to estimate factors associated with mortality rate, and year, region, age and sex were considered for inclusion. RESULTS: From 38.7 million person-years of surveillance, we identified 2961 30-day deaths in 30,923 incident E. coli BSIs. The overall 30-day case fatality risk was 9.6% (2961/30923). Calgary, Skaraborg, and western interior had significantly increased odds of 30-day mortality compared to Finland. Hospital-onset and 3GC-resistant E. coli BSIs had significantly increased odds of mortality compared to community-onset and 3GC-susceptible. The significant association between age and odds of mortality varied with sex, and contrasts were used to interpret this interaction relationship. The overall standardized 30-day mortality rate was 8.5 deaths/100,000 person-years. Sherbrooke had a significantly lower 30-day mortality rate compared to Finland. Patients that were either ≥70-years-old or male both experienced significantly higher mortality rates than those < 70-years-old or female. CONCLUSIONS: In our study populations, region, age, and sex were significantly associated with both 30-day case fatality risk and mortality rate. Additionally, 3GC resistance and location of onset were significantly associated with 30-day case fatality risk. Escherichia coli BSIs caused a considerable burden of disease from 30-day mortality. When analyzing population-based mortality data, it is important to explore mortality through two lenses, mortality rate and case fatality risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06326-x. BioMed Central 2021-06-25 /pmc/articles/PMC8229717/ /pubmed/34172003 http://dx.doi.org/10.1186/s12879-021-06326-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
MacKinnon, Melissa C.
McEwen, Scott A.
Pearl, David L.
Lyytikäinen, Outi
Jacobsson, Gunnar
Collignon, Peter
Gregson, Daniel B.
Valiquette, Louis
Laupland, Kevin B.
Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study
title Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_full Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_fullStr Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_full_unstemmed Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_short Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_sort mortality in escherichia coli bloodstream infections: a multinational population-based cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229717/
https://www.ncbi.nlm.nih.gov/pubmed/34172003
http://dx.doi.org/10.1186/s12879-021-06326-x
work_keys_str_mv AT mackinnonmelissac mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT mcewenscotta mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT pearldavidl mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT lyytikainenouti mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT jacobssongunnar mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT collignonpeter mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT gregsondanielb mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT valiquettelouis mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT lauplandkevinb mortalityinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy